New insights into the pathogenesis and management of rheumatoid arthritis  

作　　者：Shangyi Jin Jiuliang Zhao Mengtao Li Xiaofeng Zeng 

机构地区：[1]Department of Rheumatology and Clinical Immunology,Chinese Academy of Medical Sciences&Peking Union Medical College,National Clinical Research Center for Dermatologic and Immunologic Diseases(NCRC-DID),Ministry of Science&Technology,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital(PUMCH),Key Laboratory of Rheumatology and Clinical Immunology,Ministry of Education,Beijing,China

出　　处：《Chronic Diseases and Translational Medicine》2022年第4期256-263,共8页慢性疾病与转化医学（英文版）

基　　金：Chinese National Key Technology R&D Program(Grant/Award Number: 2021YFC2501300);CAMS Innovation Fund for Medical Sciences (CIFMS)(Grant/Award Number: 2021-I2M-1-005)。

摘　　要：Over the past few decades, understanding of the pathogenesis of rheumatoid arthritis (RA) has improved substantially. Insights into the cellular and molecular mechanisms involved in RA have enabled the discovery of new therapeutic targets and led to the development of biologics and targeted synthetic disease-modifying antirheumatic drugs. In parallel with the improvement in therapies, the evolution of strategies in the management of RA has also contributed considerably to better outcomes in patients. Major changes include the development of disease activity measures, formulation of the treat-to-target principles as well as increased attention to comorbidities. The presence of comorbidities such as cardiovascular diseases may increase the mortality of RA patients, affect their treatment strategies and result in worse outcomes. Therefore, prevention and management of certain high-risk comorbidities have become increasingly important in the long-term treatment of RA. In this study, we summarized new insights into the pathogenesis and management of rheumatoid arthritis and associated comorbidities, with a special focus on the 2021 update of the American College of Rheumatology (ACR) guideline for RA and key reports presented at the 2021 ACR convergence.

关 键 词：COMORBIDITY drug safety JAK inhibitor rheumatoid arthritis single-cell sequencing 

分 类 号：R593.22[医药卫生—内科学]